SCHEMBL8937433

SCHEMBL8937433

O=C(O)C=C(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
CES2 O00748 3/20 0.52
CES1 P23141 3/20 0.52
SRD5A2 P31213 1/20 0.50
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
PDPK1 O15530 1/20 0.46
GSK3B P49841 2/20 0.45
MAPK1 P28482 1/20 0.45
CYP1B1 Q16678 1/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
NR4A1 P22736 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11328609 0.94 CES2 (0.61) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL28638888 0.89 KMT2A (0.49) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL14033875 0.86 POLB (0.60) ALOX15TSHRSRD5A2CA1CA2
SCHEMBL10609744 0.84 TSHR (0.41) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL10609739 0.84 TSHR (0.41) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL11557852 0.84 LCK (0.47) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL10905923 0.82 CES2 (0.52) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL11819990 0.82 CES2 (0.52) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL10612144 0.82 GSK3B (0.44) ALOX15TSHRCES2CES1SRD5A2
SCHEMBL10612140 0.82 GSK3B (0.44) ALOX15TSHRCES2CES1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed
US-4603145-A Antiatherosclerotic diphenyl alkanamides AMERICAN CYANAMID COMPANY (US) 1986-07-29 US disclosed
US-4536346-A TREATMENT OF ATHEROSCLEROSIS AMERICAN CYANAMID COMPANY (US) 1985-08-20 US disclosed
EP-0124791-A1 Aralkanamidophenyl compounds AMERICAN CYANAMID COMPANY (US) 1984-11-14 EP disclosed